Articles les plus consultés
-
francis 13 Version sans publicité Marchés Actualités Analyses Crypto Fonds Graphiques Technique Brokers Outils Portefe...
-
6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
-
Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium 14.95 + 39.07% 0,60K Mondialisation de l'Inde. 0,4800 + 18,52% 1,80K...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation 51.30 + 10,73% 58.90K Staples Inc 9.25 + 6,81% 12,31K Delcat...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath 0.1230 + 24,24% 196,67K Neos Therapeutics I. 10.50 +16.67% 34.36K Enpha...
-
Citoyens_Français @citoyenneFrance 8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In 5.32 + 32,34% 38.64K Enphase Energy Inc 0,938 + 17,57% 10,37K Delca...
-
28 juin 2017 Nom du médicament et numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
-
Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc 1,3900 +25,23% 3,55K Alibaba 139,95 +11,35% 1,40M MoSys...
jeudi 26 avril 2018
ARI Recognized as One of the Best Workplaces in Canada for Second Consecutive Year
ARI Recognized as One of the Best Workplaces in Canada for Second Consecutive Year: Annual list honors top employers who foster a workplace culture of camaraderie and collaboration
GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018 | Business Wire
GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018 | Business Wire: GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer: Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab
Inscription à :
Articles (Atom)